The Strategic Europe Value Fund* returned -5.41% in December, finishing 2018 with
a performance of -5.86%, outperforming its index by 4.71 percentage points.
Stock selection was positive in December, with the best performing sector in terms of alpha
being Industrials, mostly due to strong stock selection. The worst performing sectors in
terms of alpha were Health Care, Utilities and Materials, with the Fund’s underweight
to both, the Utilities and Materials sector dragging on performance. December was a
difficult month for markets, with all of the Fund’s sectors closing in negative territory.
The worst performing sectors for the benchmark were Financials, Real Estate and Health
The Fund had no significant positive performers (> 50bps contribution to return) in
December, with the most significant detractor being Fresenius Medical Care. The stock
had its second profit warning during the month and the market is concerned that some
of the issues presented in 2018 are structural. This said, the Investment Adviser believes
that these issues will be addressed in 2019. The stock is currently trading on a multi-year
low valuation and the Company is investing in medium-term growth, which should be
share price accretive. Over the month, the Fund initiated a new position in Bayer, a stock
the Fund has held in the past. The decision was a valuation call, as the share price was
very attractive in the Investment Adviser’s opinion and the stock is currently unloved by
The Strategic Global Quality Fund returned -5.01% in December, outperforming its
benchmark by 2.59 percentage points. The Fund closed 2018 with a loss of -6.24%, 2.47
percentage points ahead of its benchmark. Consumer Staples and Industrials contributed
the most to alpha in December, both driven by strong stock selection. The Fund’s
underweight to the Utilities sector constituted a slight drag on relative performance. All
sectors for the Global Fund declined in December; with Energy, Financials and Industrials
being the worst performers for the benchmark.
The Fund had no significant outperformers over the month (> 50bps contribution to
return). The largest detractor to return was Fresenius Medical Care for the reasons
2018 was a challenging year for equity markets, with increased volatility, rising central
bank interest rates, a slowdown in the Eurozone, weaker Chinese growth and increased
political worries. As we move into 2019, the Investment Adviser maintain their cautious
view regarding the market. Even though there has been a partial sell off, the Investment
Adviser believes there is more to come. The team still remain concerned about the
pricing of risk assets given the overall tightening of global monetary policies and the
amount of leverage in the current economic system.
In this environment the investment team retain their preference for defensive portfolio
positioning. This said, the market has begun to move to their way of thinking, and so the
team are finding selective opportunities outside of their traditionally preferred sectors.
* EUR I Class.
The views and statements contained herein are those of Lofoten Asset Management in
their capacity as Investment Adviser to the funds as of 15/01/2019 and are based on
internal research and modelling.